Federated TRE for Clinical Trial Cohort Discovery (2026)

Why cohort discovery is the bottleneck nobody costs in

Industry feasibility benchmarks put pre-screening at 30–40% of clinical trial study start-up time, and the Tufts Center for the Study of Drug Development has repeatedly shown that roughly four in five trials miss their original enrolment timeline. The hidden cost is not recruitment itself — it is the months sponsors spend negotiating bilateral data access agreements with each hospital network, biobank, or registry just to ask the question “how many patients here meet protocol X?”. A federated TRE collapses that negotiation cycle into a one-time governance onboarding, after which any approved cohort query runs in minutes against every participating site simultaneously.

Regulators are pushing the same direction. The European Health Data Space (EHDS) Regulation, adopted in early 2025 and entering operational phase from 2026, mandates secondary use of health data through accredited health data access bodies operating under a federated architecture. The US Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule has long required that protected health information remain under the covered entity’s control during research preparatory activities — exactly what cohort discovery is. The General Data Protection Regulation (GDPR) Article 89 conditions for scientific research are easier to satisfy when source data is never transferred. A federated TRE is the operational pattern that aligns with all three.

How federated cohort discovery actually works

Step 1 — Harmonisation to a shared semantic layer

Before any query can fan out, every participating site needs its electronic health record (EHR), laboratory, imaging and genomics data mapped to a common vocabulary. The two dominant standards are FHIR R4 for transactional clinical exchange and OMOP CDM v5.4 for research-grade analytics. FHIR R4 gives you patient, condition, observation, medication and procedure resources with standardised terminologies (SNOMED CT, LOINC, RxNorm). OMOP CDM v5.4 adds the analytic layer — concept relationships, drug eras, condition eras and standardised vocabularies maintained by the Observational Health Data Sciences and Informatics (OHDSI) community. A federated TRE that supports both lets a sponsor write one cohort definition and have it execute against either schema at each site.

Step 2 — Query distribution and local execution

The sponsor authors an eligibility query — for example, “adults aged 50–75 with a recorded diagnosis of HER2-positive metastatic breast cancer, ECOG 0–1, no prior trastuzumab deruxtecan exposure, eGFR > 50 mL/min/1.73m², measurable disease per RECIST 1.1” — in a structured query language such as the OHDSI ATLAS cohort definition format or a FHIR Search query. The federated TRE serialises that query and pushes it through an authenticated channel to a lightweight agent running inside each participating institution’s network perimeter. Each agent translates the query into the local SQL dialect, executes it against the local OMOP or FHIR store, and returns only aggregate results (counts, distributions, summary statistics) — never row-level records. The source records remain inside the custodian’s perimeter throughout.

Step 3 — Aggregation, airlock and disclosure control

Aggregate results from each site are returned to the federated TRE’s central orchestration plane, where they are combined into a feasibility report. Before any output is released to the sponsor, an automated disclosure-control airlock applies small-number suppression (typically suppressing cells with counts below 5 or 10 depending on jurisdiction), k-anonymity checks, and differential privacy where required by the data custodian’s policy. The sponsor sees: total eligible patients per site, geographic distribution, age and sex breakdown, and key comorbidity prevalence. They do not see — and the architecture does not permit them to see — any individual patient record.

Step 4 — Iteration before commitment

The real operational win is iteration speed. A protocol designer can refine inclusion and exclusion criteria, widen an age range, drop a biomarker requirement, or test alternate washout periods and get a fresh feasibility count back within minutes. In a centralised model, each iteration requires a new data extract, a new transfer approval, a new ingestion cycle — typically two to six weeks. A federated TRE turns protocol optimisation from a quarterly exercise into a same-day workflow.

Centralised vs federated cohort discovery

What a production federated TRE for cohort discovery looks like

A federated TRE for multi-institution cohort discovery typically sits as a node at each data custodian — a hospital trust, a national biobank, a payer claims dataset, a primary care research network. Each node runs the same containerised stack: a query receiver, a translation layer that maps incoming queries to the local OMOP CDM v5.4 or FHIR R4 schema, an execution engine, and an outbound airlock. A central federation controller — operated by a sponsor consortium, a contract research organisation, or a public-sector data access body — handles authentication, query routing, result aggregation and audit logging. Public reference implementations of this pattern include the European Health Data and Evidence Network (EHDEN) and the Observational Health Data Sciences and Informatics (OHDSI) federated analytics network.

For sponsors, the operational gain is that one query can reach dozens of sites that would otherwise require dozens of bilateral agreements. For custodians, the gain is a participation model that does not force them to hand over patient records and lose audit visibility. The architecture, reinforced by patents such as US 12,519,781 covering federated computation over distributed health datasets, preserves custodian control by construction rather than by contract.

A practical implementation checklist

Sponsors and consortia evaluating a federated TRE for cohort discovery should validate the following before committing to a network design:

1. Standards coverage — confirm native support for FHIR R4 and OMOP CDM v5.4, plus an extension path for site-specific vocabularies (national drug codes, local lab terminologies).
2. Query expressiveness — verify the platform handles temporal logic (washout windows, observation periods), nested criteria, and biomarker-driven inclusion (genomic variants, lab thresholds) in addition to ICD/SNOMED codes.
3. Airlock policy granularity — each site must be able to set its own small-number suppression threshold, k-anonymity parameters, and differential privacy epsilon without sponsor override.
4. Audit completeness — every query, every result, every approver decision logged with non-repudiable timestamps. Custodians should be able to produce a full trail on demand for their information commissioner.
5. Regulatory mapping — explicit documentation of how the architecture satisfies HIPAA preparatory-to-research provisions, GDPR Article 89, and EHDS Chapter IV obligations for secondary use.
6. Site onboarding time — a mature federated TRE should bring a new site live in weeks, not quarters; ask for measured median time-to-first-query across recent deployments.
7. Exit and portability — the federation model should not lock a custodian into a single vendor; harmonised data assets should remain portable in open formats.

What this changes for trial design

When feasibility answers arrive in hours rather than months, protocol design itself shifts. Sponsors can afford to test five competing eligibility schemas rather than one, model the recruitment impact of dropping a single exclusion criterion before lock, and identify the three sites contributing 60% of the eligible population. They can also discover, early, that a planned trial is infeasible at the proposed criteria — itself valuable, because the alternative is discovering it twelve months into recruitment. Federated cohort discovery does not just speed up an existing workflow; it aligns trial operations with the regulatory direction set by EHDS, HIPAA and GDPR — where the default expectation is that sensitive health data stays under custodian control.

Frequently asked questions

How long does federated cohort discovery actually take?

Once a federated TRE network is established, a typical eligibility query returns aggregate counts in minutes to a few hours, depending on the complexity of the criteria and the size of each site’s warehouse. The weeks-to-months figure in industry benchmarks refers to centralised models that require new data transfer agreements and extract cycles for each study.

Can a federated TRE handle genomic eligibility criteria as well as clinical criteria?

Yes — provided each participating site has genomic variants mapped into its OMOP CDM v5.4 instance (via the OHDSI Genomic CDM extension) or exposed through FHIR Genomics resources. The query travels to the data exactly as it does for diagnosis or medication criteria, and only aggregate counts return.

How does this differ from a data lake or centralised research environment?

A centralised research environment requires patient-level data to be copied into one location under the operator’s control. A federated TRE inverts the flow: the computation moves to each custodian’s environment, executes locally, and returns only aggregate or derived outputs. The patient-level data never leaves the custodian’s perimeter.

Is federated cohort discovery compatible with HIPAA preparatory-to-research provisions?

It maps cleanly. HIPAA permits a covered entity to use protected health information for activities preparatory to research provided the information does not leave the covered entity. A federated TRE enforces that condition architecturally — the query runs inside the custodian’s environment and only aggregate counts cross the perimeter.

What standards must participating sites support?

At a minimum, FHIR R4 for transactional clinical resources and OMOP CDM v5.4 for analytic queries. Many networks also require standardised vocabularies (SNOMED CT, LOINC, RxNorm, ICD-10/11) and a documented extract-transform-load (ETL) pipeline so harmonisation quality can be audited.

How does the European Health Data Space affect cohort discovery?

EHDS mandates that secondary use of health data, including cohort discovery for research, runs through accredited health data access bodies under a federated architecture by default. Sponsors who already operate federated workflows are aligned with the regulation; sponsors relying on centralised extracts will face increasingly restrictive transfer assessments.

What is the typical site onboarding effort?

For a mature federated TRE platform with established FHIR R4 and OMOP CDM v5.4 connectors, onboarding a new site typically takes four to twelve weeks — covering ETL validation, vocabulary mapping audit, network integration, governance sign-off, and a test-query dry run. Sites with pre-existing OMOP instances onboard fastest.